Nanobiotechnology Global Strategic Research Report 2024

Market to Surpass $160 Billion by 2030 from $100 Billion in 2023 as Nanobiotechnology to Become Viable for All Drug Development Stages

The “Nanobiotechnology – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

Global Nanobiotechnology Market to Reach $160.3 Billion by 2030

The global market for Nanobiotechnology estimated at US$100 Billion in the year 2023, is projected to reach a revised size of US$160.3 Billion by 2030, growing at a CAGR of 7% over the analysis period 2023-2030.

Efforts are focused on enhancing performance to introduce new manufacturing methods for nanomaterials, driving investments in nanobiotechnology by both private and public entities.

Pharmaceuticals & Biotechnology End-Use Industry, one of the segments analyzed in the report, is expected to record 7.6% CAGR and reach US$110.3 Billion by the end of the analysis period. Growth in the Medical Devices End-Use segment is estimated at 5.7% CAGR for the next 7-year period.

Industry consolidation sharpens competitiveness, while evolving regulatory frameworks grapple with technological advancements, particularly in areas like quantum dot patents. Miniaturized liquid handling emerges as a progressive trend, alongside advancements in nanotechnology-enabled drug delivery systems, further accelerated by key drivers such as patent expiries and the reexamination of unused drugs.

The U.S. Market is Estimated at $30.6 Billion, While China is Forecast to Grow at 6.5% CAGR

The rise of developing countries looms ahead as a prominent trend, particularly in the domain of nanomaterials and nanoparticles, which are experiencing robust activity. Notably, the United States leads in government funding in this sector. Increasing awareness of nanotechnology’s potential fuels demand for novel products, especially in nano-enabled drug discovery, which holds significant promise.

The Nanobiotechnology market in the U.S. is estimated at US$30.6 Billion in the year 2023. China, the world’s second largest economy, is forecast to reach a projected market size of US$27.6 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.6% and 5.3% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Key Attributes:

Report Attribute Details
No. of Pages 212
Forecast Period 2023 – 2030
Estimated Market Value (USD) in 2023 $100 Billion
Forecasted Market Value (USD) by 2030 $160.3 Billion
Compound Annual Growth Rate 7.0%
Regions Covered Global

MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • A Curtain Raiser
  • Recent Market Activity
  • Nanobiotechnology – The Next Big Thing
  • An Insight into the Global Nanobiotechnology Market
  • Major Market Drivers
  • Where Conventional Molecular Science Falls Short.Nanobio Steps In
  • Nanotechnology Revolutionizes Pharmaceuticals & Healthcare Sector
  • Nanomedicine Market to Achieve Phenomenal Growth
  • Opportunities Galore for Nanomedicine
  • Drug Delivery – A Promising Application Area for Nanotechnology
  • Nanotechnology Offers Huge Potential in Brain Disorder Treatment
  • High Demand for Nanobots and Nano Healthcare Devices
  • Nanotechnology Gaining Prominence for Treatment of Cancer
  • Nanotechnology in Drug Delivery: A Specialized Market Opportunity
  • Commercialization of Nanotechnology-based Medical Products Gains Momentum
  • Nanodiagnostic Products to Witness Strong Demand Growth
  • Dendrimers Serve as a Base to Build Multifunctional Nanodevices
  • Nanotechnology Rescues Poor Water Soluble Drugs from Abandonment
  • Huge Opportunities for Nanomaterials in the Medical Field
  • Commercial Opportunities in Healthcare Sector
  • Future Possibilities
  • Global Market for Fullerenes – An Insight
  • Dawn Breaks on Nanobiotechnology
  • Demystifying the Intriguing World of Nanobiotech
  • A Meeting Place of Medicine’s Best Solutions
  • Nanobiotechnology to Become Viable for All Drug Development Stages
  • Nanoparticles: The Foundation of Nanobiotechnology
  • Improved Optical Properties and Stability of Nanoparticles
  • Nanoemulsions
  • The Promise of Nanobiotechnology
  • Biological Weaponries against Diseases Come in Small Packages
  • Proffered Benefits of Nanobiotechnology
  • Opportunity & Beyond
  • Nanobiotechnology – Will it Live Up to the Expectations?
  • The Future of Nanobiotechnology: Shape of Things to Come
  • Nanobiotechnology: The Outer Limits
  • Futuristics: A Rumination
  • Conclusions
  • Nanobiotechnology – Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

MARKET TRENDS & DRIVERS

  • Present Status and Future Opportunities
  • Outlook
  • Developing Countries to Rise over the Horizon
  • Nanomaterials & Nanoparticles Witness Robust Activity
  • Focus on Improved Performance to Bring New Manufacturing Methods for Nanomaterials
  • Why Invest in Nanobiotechnology?
  • Private and Public Companies to Step Up Funding on Nanotechnology
  • United States Lead the Way in Government Funding
  • Increasing Awareness on Technology to Drive Growth
  • Demand for Novel Products to Push Up Growth
  • Nano-Enabled Drug Discovery Holds Tremendous Potential
  • Consolidation Sharpens the Industry’s Edge
  • The Regulatory Framework Evolves with the Technology
  • Quantum Dot Patents Pose Legal Tangles
  • Miniaturized Liquid Handling Becomes Progressive
  • Trends in Nanotechnology Enabled Drug Delivery Systems
  • Patent Expiries: A Key Driver
  • Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs

FOCUS ON SELECT PLAYERS (Total 79 Featured)

  • Ablynx NV (Belgium)
  • Arrowhead Pharmaceuticals, Inc. (USA)
  • Avadel Pharmaceuticals plc (Ireland)
  • CaPtivate Pharmaceuticals LLC (USA)
  • Celgene Corporation (USA)
  • ELITechGroup (France)
  • GlaxoSmithKline Plc. (UK)
  • Johnson & Johnson (USA)
  • Merck & Co., Inc. (USA)
  • NanoBio Corporation (USA)
  • Nanophase Technologies Corporation (USA)
  • pSivida Corp. (USA)
  • Sigma-Aldrich Corp. (USA)
  • Starpharma Holdings Ltd. (Australia)
  • Vectura Group plc (UK)

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”